Dr. Evan Levine tackles a drug that is often prescribed to help children perform better — a phenomenon he calls “borderline ...

Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

A major new study shows that giving heart attack patients a cholesterol-lowering combo treatment early on – not months later ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

The differences in risk of sudden cardiac death varied by age and how long people took antidepressants, with people taking ...

The rise in the use of certain weight loss drugs is being credited not only for its potential to help people shed pounds, but ...